Spots Global Cancer Trial Database for Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

Official Title: Precision Chemotherapy Based on Organoid for Colorectal CancerPatient-Derived Tumor Organoid Drug Sensitivity for Colorectal Cancer: A Prospective, Multicentre，Randomized, Controlled Trial

Study ID: NCT05832398

Conditions

Colorectal Cancer

Interventions

FOLFOX , FOLFIRI or FOLFOXIRI regimens

FOLFOX or CapeOX regimens

Study Description

Brief Summary: The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.

Detailed Description: Fluorouracil-based chemotherapy is the standard treatment for stage IV colorectal cancer patients. However, the effects of chemotherapy remains limited. Patient-derived tumor organoids are increasingly used as tools for drug test and predicting drug response in the clinic, and have been showed to faithfully predict clinical outcomes of patients with CRC. A prospective clinical trial is needed to validate whether the in vitro sensitivity to chemotherapy regimens in organoids drug test is associated with a longer PFS in stage IV colorectal cancer.